Dietary fiber intake and gut microbial fiber fermentation capacity are associated with favorable clinical outcomes following immune checkpoint blockade
This research investigates the relationship between dietary fiber intake, the gut microbiome, and the effectiveness of immune checkpoint blockade (ICB) therapy in cancer patients. The study found that higher dietary fiber intake was associated with longer progression-free and overall survival in patients receiving ICB. Additionally, the abundance of butyrate-producing genes in the gut microbiome was also linked to improved ICB outcomes. These findings suggest that diet and the gut microbiome may play a role in modulating the response to ICB therapy, potentially leading to new strategies for improving cancer treatment.